Compare SPRO & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | TAYD |
|---|---|---|
| Founded | 2013 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.7M | 132.1M |
| IPO Year | 2017 | N/A |
| Metric | SPRO | TAYD |
|---|---|---|
| Price | $2.28 | $63.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 281.7K | 7.8K |
| Earning Date | 11-13-2025 | 01-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.72 |
| Revenue | $40,549,000.00 | ★ $44,593,219.00 |
| Revenue This Year | N/A | $10.81 |
| Revenue Next Year | N/A | $8.37 |
| P/E Ratio | ★ N/A | $22.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $29.50 |
| 52 Week High | $3.22 | $62.00 |
| Indicator | SPRO | TAYD |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 78.49 |
| Support Level | $2.26 | $58.58 |
| Resistance Level | $2.37 | $62.00 |
| Average True Range (ATR) | 0.07 | 2.43 |
| MACD | -0.00 | 0.55 |
| Stochastic Oscillator | 12.12 | 100.00 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.